Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...
ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to ...
ACCORD-2 trial shows AXS-05 significantly delays Alzheimer’s agitation relapse; long-term safety established, NDA submission planned for 2025. Axsome Therapeutics has announced positive results from ...
Agitation reported in nearly 50% of patients with Alzheimer’s disease FDA Fast Track designation previously received for AXS-05 for Alzheimer’s disease agitation Second indication for AXS-05 in ...
- Study Achieves Secondary End Point: Demonstrates Clinical Reduction, approaching statistical significance, at Week Two, in Agitation in Dementia due to Alzheimer’s - POTOMAC, Md.--(BUSINESS ...
Please provide your email address to receive an email when new articles are posted on . There were no new safety signals, and treatment-emergent adverse events were comparable in the AXS-05 group and ...
SAN DIEGO — New data confirmed the safety and efficacy of AXS-05, a combination of dextromethorphan and bupropion, for the treatment of agitation associated with Alzheimer’s disease (AD). In the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback